Religare files criminal complaint against promoters Singh brothers
The complaint also names REL ex-CMD Sunil Godhwani, among other directors, for cheating, fraud and misappropriation of funds to the tune of Rs 740 crore.
New Delhi: Religare Enterprises Ltd (REL) Wednesday said its subsidiary Religare Finvest (RFL) has lodged a criminal complaint with the Economic Offences Wing of the Delhi Police against promoters Malvinder Mohan Singh and Shivinder Mohan Singh. The complaint also names REL ex-CMD Sunil Godhwani, among other directors, for cheating, fraud and misappropriation of funds to the tune of Rs 740 crore.
"Religare Finvest, a subsidiary of Religare Enterprises has filed a criminal complaint with the Economic Offences Wing of the Delhi Police against the promoters of REL Malvinder Mohan Singh and Shivinder Mohan Singh as well as REL's former CMD, Sunil Godhwani, N K Ghoshal, the directors and officers of the promoter entities and other unknown persons for various offences under the Indian Penal Code," REL said in a regulatory filing.
The complaint has been registered for various offences including cheating, criminal breach of trust, misappropriation, fraud and forgery and criminal conspiracy, REL said.
"The complaint was filed basis internal inquiries (including an independent forensic review) undertaken by the new RFL board and management," it said.
REL was controlled by the warring Singh brothers until February 2018.
Post their exit from the board of REL in February 2018, the boards of REL and RFL have been re-constituted.
Pursuant to reconstitution, the REL and RFL boards now consist of professionals widely recognised in their respective fields, who are unconnected to the promoters, it said further.
"The reconstituted boards have appointed new professional management to manage the affairs of REL and its subsidiaries. Through the inquiries undertaken by the new RFL Board and management it has discovered syphoning and misappropriation of funds of RFL amounting to approx Rs 740 crores in aggregate through loans to entities that are controlled by, connected to or known to the promoters or their associates," REL said.
Earlier this month, the feud between the brothers took an ugly turn when they allegedly came to blows, following which the younger brother Shivinder said the incident had closed any possibility of them working together to resolve the issues.
The relationship between the Singh brothers, erstwhile promoters of Fortis Healthcare and Ranbaxy, went sour after allegations of fund diversion from the healthcare chain emerged.
It reportedly aggravated further overpayment of arbitration award to Daiichi Sankyo. Shivinder had offered to pay his share of the Rs 3,500 crore award to the Japanese drugmaker in a dispute related to the acquisition of Ranbaxy Laboratories.
Earlier in September this year, Shivinder had filed a petition before the National Company Law Tribunal (NCLT), alleging that collective and ongoing actions of Malvinder and ex-Religare chief Sunil Godhwani led to a systemic undermining of the interests of companies and their shareholders.
Daiichi SankyoDelhi policeDirectoreconomic offfences wingEGMeowex cmdfeudfinancial transactionforgedFortisFortis HealthcarehindranceillegalinterventionMalvinder SinghNCLTpenal codeRanbaxyrelReligareshareholderShivinder SinghSunil Godhwani
Source : PTIFarhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd